JP2019512222A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512222A5
JP2019512222A5 JP2018546577A JP2018546577A JP2019512222A5 JP 2019512222 A5 JP2019512222 A5 JP 2019512222A5 JP 2018546577 A JP2018546577 A JP 2018546577A JP 2018546577 A JP2018546577 A JP 2018546577A JP 2019512222 A5 JP2019512222 A5 JP 2019512222A5
Authority
JP
Japan
Prior art keywords
polypeptide
terminal
mhc
amino acid
multimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546577A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512222A (ja
JP7372036B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020480 external-priority patent/WO2017151940A2/en
Publication of JP2019512222A publication Critical patent/JP2019512222A/ja
Publication of JP2019512222A5 publication Critical patent/JP2019512222A5/ja
Application granted granted Critical
Publication of JP7372036B2 publication Critical patent/JP7372036B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546577A 2016-03-03 2017-03-02 T細胞調節多量体ポリペプチド及びその使用方法 Active JP7372036B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662303268P 2016-03-03 2016-03-03
US62/303,268 2016-03-03
PCT/US2017/020480 WO2017151940A2 (en) 2016-03-03 2017-03-02 T-cell modulatory multimeric polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019512222A JP2019512222A (ja) 2019-05-16
JP2019512222A5 true JP2019512222A5 (https=) 2020-04-09
JP7372036B2 JP7372036B2 (ja) 2023-10-31

Family

ID=59743280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018546577A Active JP7372036B2 (ja) 2016-03-03 2017-03-02 T細胞調節多量体ポリペプチド及びその使用方法

Country Status (9)

Country Link
US (2) US20190046648A1 (https=)
EP (1) EP3423078A4 (https=)
JP (1) JP7372036B2 (https=)
KR (1) KR20180132070A (https=)
CN (1) CN109414498A (https=)
AU (1) AU2017225787B2 (https=)
CA (1) CA3014466A1 (https=)
IL (1) IL261402A (https=)
WO (1) WO2017151940A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2894511C (en) 2012-12-11 2021-12-07 Albert Einstein College Of Medicine Of Yeshiva University Methods for high throughput receptor:ligand identification
CN109689096A (zh) 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
EP3634449A4 (en) 2017-05-08 2021-03-17 Gritstone Oncology, Inc. ALPHAVIRUS NEOANTIGEN VECTORS
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ,インコーポレーテッド コンジュゲーション部位を有するt細胞調節多量体ポリペプチド及びその使用方法
CN111886241A (zh) * 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
JP2021524247A (ja) * 2018-05-23 2021-09-13 グリットストーン バイオ インコーポレイテッド 免疫チェックポイント阻害剤の共発現ベクター
EP3935079A4 (en) * 2019-03-06 2023-03-22 Cue Biopharma, Inc. T-CELL MODULATING ANTIGEN PRESENT POLYPEPTIDES AND METHODS OF USE THEREOF
KR20220015382A (ko) * 2019-05-29 2022-02-08 큐 바이오파마, 인크. 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
US20220089757A1 (en) * 2019-06-05 2022-03-24 Adagene Pte. Ltd. Anti-cd137l antibodies and methods of using same
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ, インコーポレイテッド 多量体t細胞調節性ポリペプチド及びその使用方法
CA3146591A1 (en) * 2019-09-20 2021-03-25 Ronald D. Seidel Iii T-cell modulatory polypeptides and methods of use thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
WO2022056014A1 (en) * 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
MX2023008966A (es) * 2021-02-07 2023-09-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticuerpo biespecifico.
CN120202214A (zh) * 2022-10-28 2025-06-24 Fbd生物制品有限公司 经工程改造的4-1bbl变体及其使用方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
JP2001505060A (ja) * 1997-01-14 2001-04-17 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド 腫瘍壊死因子受容体 5
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
AU2002322211A1 (en) * 2001-07-12 2003-01-29 Canvac Methods and compisitions for activation human t cells in vitro
WO2003040307A2 (en) * 2001-07-27 2003-05-15 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
US7087225B2 (en) * 2001-08-16 2006-08-08 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US6911321B2 (en) * 2001-12-19 2005-06-28 Genentech, Inc. Non-human primate Fc receptors and methods of use
US8895020B2 (en) * 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
JP5710866B2 (ja) * 2006-01-23 2015-04-30 ノボザイムス アクティーゼルスカブ リパーゼ活性を有するポリペプチド及びそれをコードするポリヌクレオチド
WO2008116468A2 (en) * 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
CN102898504B (zh) * 2012-10-23 2014-08-06 中国农业大学 抗氧化活性合成肽及其用途
JP6595988B2 (ja) * 2013-07-19 2019-10-23 ヴィブ ブイゼットダブリュー ターゲットされる修飾tnfファミリーメンバー
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
JP2017525370A (ja) * 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインを調製および使用する方法
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2019512222A5 (https=)
JP2019516665A5 (https=)
JP2019522466A5 (https=)
JP2019522465A5 (https=)
JP2020511949A5 (https=)
JP2022515330A5 (https=)
JP2022536581A5 (https=)
JP6923714B2 (ja) Mhcクラスii拘束性mage−a3を認識するt細胞受容体
IL308851B2 (en) T-cell modulatory multimeric polypeptides and methods of use thereof
JP2021500855A5 (https=)
JP2023059873A5 (https=)
IL275307A (en) SYNTAC polypeptides and their uses
JP2020074776A5 (https=)
JP2017527272A5 (https=)
IL272085B2 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
JP2017509335A5 (https=)
JP2017519491A5 (https=)
JP2019514358A5 (https=)
JP2021527700A5 (https=)
JP2015535816A5 (https=)
JP2018525006A5 (https=)
JP2016502512A5 (https=)
JP2015525217A5 (https=)
FI2968461T3 (fi) Fuusioproteiineja, jotka käsittävät pdgf:ää ja vegf:ää sitovia osia, ja menetelmiä niiden käyttämiseksi
JP2018519803A5 (https=)